Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports outline breast cancer research from University of Jena
May 7th, 2009
According to a study from Jena, Germany, "In breast cancers, the gene for the growth factor receptor HER2 can be amplified leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly significantly but eventually many patients relapse." "In this study, CETC were monitored using the Maintrac(A (R)) method during adjuvant trastuzumab treatment and during subsequent treatment with capecitabine/lapatinib. In one patient, trastuzumab led to marginal reduction in CETC with disease progress. The combination of capecitabine/lapatinib was preliminarily capable to eliminate all CETC, however, CETC...
Source: Women's Health Weekly (2009-05-07)
|
